Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Open AMGN dashboard ↗BioNTech SE American Depositary Share
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Open BNTX dashboard ↗